Back to today’s briefing

Story perspectives

FOIA Requests Surge Amid GLP-1 Drug Scrutiny

1/9/2025

31 4

Summary

Story summary

FOIA requests skyrocketed over the past year, focusing on GLP-1 weight-loss drugs from Eli Lilly and Novo Nordisk. This surge, fueled by intense demand and legal scrutiny, uncovers competitive insights and hints at looming litigation. Media inquiries into pricing issues and FDA inspections reflect growing public and legal unease surrounding these pharmaceutical giants.

1 of 1

Story summary

FOIA requests skyrocketed over the past year, focusing on GLP-1 weight-loss drugs from Eli Lilly and Novo Nordisk. This surge, fueled by intense demand and legal scrutiny, uncovers competitive insights and hints at looming litigation. Media inquiries into pricing issues and FDA inspections reflect growing public and legal unease surrounding these pharmaceutical giants.